Order byBest matchMost fresh
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
One estimate of the profit hit from Trump's executive order on drug pricing
Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels could result in 15% operating profit cuts in the industry.
Merck’s New Keytruda Shot Is a Rare Real-Time ‘Product Hop’ (1)
Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, expand access, and save more lives, the company says. But by shifting patients to a version protected by newer patents,
Pharma stocks recover from initial shock of Trump's drug pricing order
Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's sweeping executive order to slash prescription drug prices would be difficult to implement and face legal challenges.
Trump's plans to assess tariffs on imported drugs could raise prices, cause drug shortages
Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on prescription drug imports.
Yahoo Finance2d
Merck & Co., Inc. (MRK)
Pharmacy stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck (MRK), are moving to the downside after US President Trump said he will cut drug prices by over 50%. To watch more ...
Feedback